NASDAQ: AZTAAzenta Inc Stock
$25.03-0.22 (-0.87%)
Updated Apr 21, 2025
AZTA Price
$25.03
Fair Value Price
-$14.95
Market Cap
$1.14B
52 Week Low
$24.06
52 Week High
$63.58
P/E
-8.15x
P/B
0.67x
P/S
3.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$649.52M
Earnings
-$161.79M
Gross Margin
41.7%
Operating Margin
-24.82%
Profit Margin
-24.9%
Debt to Equity
0.19
Operating Cash Flow
$54M
Beta
1.55
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AZTA Overview
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AZTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
AZTA
Ranked#25 of 41
Ranked#25 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.91 | B | |
| $89.60 | B | |
| $58.31 | B |
Be the first to know about important AZTA news, forecast changes, insider trades & much more!
AZTA News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AZTA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AZTA ($25.03) is overvalued by 267.44% relative to our estimate of its Fair Value price of -$14.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AZTA ($25.03) is not significantly undervalued (267.44%) relative to our estimate of its Fair Value price of -$14.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AZTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AZTA due diligence checks available for Premium users.
Valuation
AZTA fair value
Fair Value of AZTA stock based on Discounted Cash Flow (DCF)
Price
$25.03
Fair Value
-$14.95
Undervalued by
267.44%
AZTA ($25.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZTA ($25.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AZTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.15x
Industry
38.94x
Market
27.14x
AZTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
3.49x
AZTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AZTA's financial health
Profit margin
Revenue
$147.5M
Net Income
-$13.3M
Profit Margin
-9%
AZTA's Earnings (EBIT) of -$161.18M... subscribe to Premium to read more.
Interest Coverage Financials
AZTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.0B
Liabilities
$322.2M
Debt to equity
0.19
AZTA's short-term assets ($846.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZTA's short-term assets ($846.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$30.6M
Investing
$76.3M
Financing
-$5.1M
AZTA's operating cash flow ($54.49M)... subscribe to Premium to read more.
Debt Coverage Financials
AZTA vs Medical Stocks
Azenta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.